Benuvia Operations Signs Research and Manufacturing Agreement with Leading Ivy League Research University
Company will provide pharmaceutical-grade psychedelic active ingredient to advance innovative scientific research focused on addressing unmet patient needs
ROUND ROCK, Texas, November 13, 2025 – Benuvia Operations, LLC (Benuvia), a global contract development and manufacturing organization, today announced that it has signed a research and manufacturing agreement with a leading Ivy League research university. Under the terms of the agreement, Benuvia will provide the university pharmaceutical-grade DMT fumarate, a psychedelic active pharmaceutical ingredient (API), to support the school’s research and development initiatives.
“We are dedicated to advancing research in psychedelic therapy and are excited to begin this new collaboration,” said Terry Novak, CEO of Benuvia. “Psychedelic therapy has received growing recognition for its potential to address various psychological challenges, including depression, anxiety, PTSD, and addiction. We are proud to be this university’s partner of choice as they seek to develop new and innovative therapies that address unmet patient needs.”
DMT fumarate is the fumarate salt form of N,N-dimethyltryptamine (DMT), a naturally occurring psychedelic compound found in various plants and animals. It is known for its powerful and short-lasting psychoactive effects. DMT primarily acts on serotonin receptors, particularly 5-HT2A, leading to intense visual and auditory hallucinations. It is currently being investigated for its potential therapeutic applications in treating various psychological conditions.
Benuvia operates a fully integrated, FDA-audited, and DEA-registered manufacturing facility in Round Rock, Texas. The company provides comprehensive services including drug substance and drug product manufacturing, analytical development, stability programs, and regulatory support for DEA Scheduled I-V controlled substances. Benuvia’s cGMP-certified processes ensure unmatched quality, making the company the trusted choice for synthetic cannabinoids and psychedelics.
About Benuvia Operations, LLC
Benuvia Operations, LLC is a U.S.-based global Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) supplier servicing pharmaceutical and biotech companies. The company provides development and manufacturing services for small-molecule APIs and finished dosage products with extensive experience with cannabinoids, psychedelics, and other controlled substances. Benuvia operates an 83,000 square foot best-in-class manufacturing facility in Round Rock, Texas that can safely and securely handle Schedule I-V controlled substances products, offering comprehensive solutions for companies throughout the entire drug development lifecycle – from API synthesis, clinical trial supply, through commercial production. Learn more at www.benuvia.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “anticipate’, “believe”, “could”, “estimate”, “upcoming”, “expect”, “intend”, “may”, “plan”, “redirect”, “project”, “will”, and similar terms and phrases may be used to identify forward-looking statements in this press release. Our operations involve risks and uncertainties many of which are outside our control and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements should be considered together with the risks and uncertainties discussed in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.